siRNA (small interfering Ribonucleic acid) for specifically inhibiting XOR (oxidoreductase) gene expression and application of siRNA
A gene expression, species-specific technology, applied in the field of siRNA
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0031] Embodiment 1, siRNA design and synthesis
[0032] Obtain the full-length sequence of human XOR mRNA (NM_000379.3) from the National Center for Biotechnology Information (NCBI) database, according to the principle of RNAi, combined with design software, and on the basis of experiments, design and synthesize and screen for 4 transcripts An effective 21nt siRNA against human XOR gene was produced. A BLAST comparison check was performed to ensure that there was no homology to other genes.
[0033] The XOR siRNA sequence is:
[0034] 5'-CGGAAGAGUGAGGUUGACAAGUUCA-3' (sense strand)
[0035] 5'-UGAACUUGUCAACCUCACUCUUCCG-3' (antisense strand)
[0036] Chemically synthesized by Shanghai Yingwei Jieji Trading Co., Ltd. (factory address: 1711, Nanyin Building, No. 2 Dongsanhuan North Road, Shanghai, Zip Code: 200051): using NTP as raw material, using ABI3900 nucleic acid synthesizer to chemically synthesize single-stranded RNA , and finally each single-stranded RNA is anneale...
Embodiment 2
[0037] Example 2, the effect of XOR siRNA on the expression of XOR gene in L02 cells in vitro
[0038] 1. Group transfection
[0039] Spread L02 cells evenly in a 6-well plate and divide them into 4 groups:
[0040] High-fat experiment group: DMEM / F12 medium containing 10% (volume percentage) inactivated neonatal bovine serum, 666 μmol / L sodium oleate and 333 μmol / L sodium palmitate; transfection 200 pmol Example 1 XOR siRNA.
[0041] High-fat control group: DMEM / F12 medium containing 10% (volume percentage) inactivated neonatal bovine serum, 666 μmol / L sodium oleate and 333 μmol / L sodium palmitate; transfection 200 pmol Example 1 negative control siRNA.
[0042] Normal experimental group: DMEM / F12 medium containing 10% (volume percent) inactivated neonatal bovine serum, 100 U / ml penicillin and 100 mg / ml streptomycin; transfected with 200 pmol of the XOR siRNA of Example 1.
[0043] Normal control group: DMEM / F12 medium containing 10% (volume percentage) inactivated neon...
Embodiment 3
[0048] Example 3, the effect of XOR siRNA on L02 cell lipid change in vitro
[0049] 1. Group transfection
[0050] The L02 cells were spread evenly in a 6-well plate and divided into 4 groups. Concrete grouping is with the step one of embodiment 2.
[0051] 2. The effect of XOR siRNA on lipid change of L02 cells in vitro
PUM
Abstract
Description
Claims
Application Information
- R&D Engineer
- R&D Manager
- IP Professional
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com